The Quest to Unlock the Brain’s Therapeutic Potential

Deep Science Ventures and Medicines Discovery Catapult are joining forces to address one of the most significant challenges in medicine: delivering treatments to the brain. By merging their strengths in venture-building and drug discovery, this partnership seeks innovative solutions to help life-changing medications penetrate the blood-brain barrier and access the central nervous system. Despite scientific progress uncovering numerous promising targets for neurological disorders, the effective delivery of treatments to the brain continues to be a major hurdle. With over 40% of the global population impacted by CNS diseases, enhancing access to targeted therapies could play a crucial role in alleviating a substantial source of illness and disability worldwide.

According to Precedence Research, the CNS Drug Discovery Market was valued at USD 9.80 billion in 2025 and is projected to grow from USD 10.86 billion in 2026 to approximately USD 27.55 billion by 2035, expanding at a CAGR of 10.90% from 2026 to 2035, driven by the growing prevalence of CNS disorders.

Expanding Access Through Brain-Entry Innovation

Addressing critical healthcare gaps could improve patient outcomes while creating clinical and commercial opportunities for biotech and pharma companies. New solutions may expand access for rare neurological disorders and broader underserved populations, including patients with Alzheimer’s, Parkinson’s, and brain cancers. The partnership will begin with a detailed review of the medicine’s landscape to identify innovation opportunities and systemic gaps in brain-entry technologies. Its long-term goal is to spin out high-impact ventures that meet investment criteria, provide pre-seed funding, and build future founding teams around pre-scoped opportunities, reducing risk in the traditional founder model across multiple sectors.

Tackling the Blood-Brain Barrier Challenge

The blood-brain barrier presents one of the most intricate challenges in contemporary medicine, particularly given that over 40% of the global population suffers from neurological conditions. Overcoming the obstacles to brain entry could pave the way for groundbreaking advancements in CNS therapeutics, addressing significant unmet medical needs. By merging venture creation expertise with drug discovery capabilities, this collaboration aspires to foster an efficient environment for developing solutions to the CNS delivery gap. Additionally, the partnership aims to identify innovative technologies that can significantly benefit patients and society, enhance the U.K. CNS innovation ecosystem, and expedite the delivery of new medicines to those in need.

A recent report by Precedence Research highlights that the CNS Drug Discovery Market is benefiting from advancements and investment in brain-delivery technologies.